DekaBank Deutsche Girozentrale’s Puma Biotechnology PBYI Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,000	Closed	-$71K	–	1411
2021 Q2	$71K	Hold	8,000	–	–	﹤0.01%	1340
2021 Q1	$74K	Hold	8,000	–	–	﹤0.01%	1296
2020 Q4	$80K	Hold	8,000	–	–	﹤0.01%	1283
2020 Q3	$78K	Buy	+8,000	New	+$81.5K	﹤0.01%	1146
2020 Q1	–	Sell	-5,158	Closed	-$44K	–	1128
2019 Q4	$44K	Sell	5,158 -8,500	-62%	-$70.4K	﹤0.01%	1099
2019 Q3	$152K	Sell	13,658 -8,500	-38%	-$91.8K	﹤0.01%	882
2019 Q2	$282K	Buy	22,158 +11,658	+111%	+$268K	﹤0.01%	980
2019 Q1	$461K	Buy	10,500 +2,000	+24%	+$61.1K	﹤0.01%	915
2018 Q4	$182K	Sell	8,500 -2,000	-19%	-$60K	﹤0.01%	978
2018 Q3	$461K	Sell	10,500 -300	-3%	-$14.5K	﹤0.01%	936
2018 Q2	$609K	Sell	10,800 -1,000	-8%	-$58K	﹤0.01%	865
2018 Q1	$779K	Buy	+11,800	New	+$884K	0.01%	778
2015 Q4	–	Sell	-2,700	Closed	-$204K	–	1120
2015 Q3	$204K	Buy	2,700 +100	+4%	+$9.46K	﹤0.01%	864
2015 Q2	$303K	Buy	+2,600	New	+$471K	﹤0.01%	800

Other funds holding PBYI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

DekaBank Deutsche Girozentrale's PBYI Position: Q3 2021 in Review

DekaBank Deutsche Girozentrale sold out of Puma Biotechnology (PBYI) in Q3 2021, closing a stake of 8,000 shares — an estimated $71K sold.

DekaBank Deutsche Girozentrale first reported a position in PBYI in Q2 2015 and held it in 14 quarters. The position peaked at $779K in Q1 2018. 115 funds tracked by Wall St. Rank hold PBYI as of Q3 2021.

DekaBank Deutsche Girozentrale reported no remaining Puma Biotechnology position as of Q3 2021 after selling out during the quarter.
DekaBank Deutsche Girozentrale sold 8,000 Puma Biotechnology shares in Q3 2021, an estimated $71K.
DekaBank Deutsche Girozentrale first reported a position in Puma Biotechnology in Q2 2015 and held it in 14 quarters.
DekaBank Deutsche Girozentrale's Puma Biotechnology position peaked at $779K in Q1 2018.
115 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2021.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q3 2021, filed 22 Oct 2021.